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Natural products are gaining increased applications in drug discovery and development. Being
chemically diverse they are able to modulate several targets simultaneously in a complex system.
Analysis of gene expression becomes necessary for better understanding of molecular mechanisms.
Conventional strategies for expression profiling are optimized for single gene analysis. DNA
microarrays serve as suitable high throughput tool for simultaneous analysis of multiple genes. Major
practical applicability of DNA microarrays remains in DNA mutation and polymorphism analysis. This
review highlights applications of DNA microarrays in pharmacodynamics, pharmacogenomics,
toxicogenomics and quality control of herbal drugs and extracts.
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Introduction
Understanding the functions of genes is a major post-genomics
challenge. Strategies like proteomics, transcriptomics, meta-
bolomics are implemented to assign the role of genes in
molecular networks. The gene expression profile of a cell
determines its phenotype, function and response to the
environment. The complement of genes expressed by a cell
is very dynamic and responds rapidly to external stimuli.
Therefore, analysis of gene expression becomes necessary for
providing clues about regulatory mechanisms, biochemical
pathways and broader cellular function. Conventional strate-
gies for expression profiling such as northern blot, reverse
northern blot, reverse transcriptase-polymerase chain reaction
(RT–PCR), nuclease protection, enzyme-linked immunosor-
bent assay (ELISA), western blot, in situ hybridization and
immunohistochemistry are optimized for single gene analysis.
Although, it is possible to modify at least some of these
techniques for multiplexing, the procedure becomes increas-
ingly technically cumbersome. For genome wide expression
analysis it is necessary to develop technologies having high
degree of automation, since in any living organism thousands
of genes and their products function in a complicated and
orchestrated way. DNA microarrays were developed in
response to the need for a high-throughput, efficient and
comprehensive strategy that can simultaneously measure all
the genes, or a large defined subset, encoded by a genome
(1,2). Several different methodologies including differential
display PCR, northern blots (3), quantitative PCR, serial
analysis of gene expression (SAGE) (4,5) and TIGR Ortho-
logous Gene Alignments (TOGA) (6,7) are used alongside
microarrays as research tools.
With an initial focus in the post-genomic era on tracking
gene expression changes for target identification, microarray
applications soon widened to span the entire drug discovery
pipeline (8–10). DNA microarrays are being used to study the
transcriptional profile in various physiological and pathologi-
cal conditions, leading to the mining of novel genes and
molecular markers for diagnosis, prediction or prognosis of
those specific states (11,12).
Success in the DNA microarray field has led to protein array
development (13–15). Protein microarrays are mainly applied
to protein function studies, screening the production
of antibodies (16) and recombinant proteins (17), discovery
of proteins implicated in disease or those that are potential
drug targets, rapid detection or diagnosis of disease (18,19)
screening for protein–protein, DNA–protein and enzyme–
substrate interactions (20,21). High-density human protein
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length human gene clones and the vast idiosyncrasies of
proteins with respect to stability and structure (22). Although
protein microarrays may not have reached the stage of
maturity of DNA microarrays, recent developments have
shown that many of the barriers holding back the technology
can be overcome (23,24).
Recently cell-based arrays employing matrices of living
cells engineered to express select proteins have rapidly
emerged as versatile tools for the high-throughput analysis of
gene function. Such arrays can facilitate genome-scale studies
on different aspects of protein function, including biochemical
activities, gene disruption phenotypes and protein–protein
interactions (25,26). Another version of living arrays called
transfection microarray has been demonstrated as an alter-
native to protein microarrays for the identification of drug
targets, and as an expression cloning system for the discovery
of gene products that alter cellular physiology (27). A siRNA
transfected cell microarray has been developed to facilitate
large-scale, high-throughput functional genomics studies using
RNAi (28).
Chemical microarrays, which are arrays of small organic
compounds, represent a novel approach towards analysis of
chemical libraries. They are widely used to analyze the
interaction of proteins with organic compounds in a miniatur-
ized and high-throughput fashion (29,30). Several modified
technologies spanning wide range of macromolecular micro-
arrays to cell arrays have opened new horizons in molecular
and physiological systems.
The DNA Microarray
DNA microarray is an orderly arrangement of thousands of
oligonucleotides or identified sequenced genes printed on an
impermeable solid support, usually glass, silicon chips or
nylon membrane. A number of terms such as DNA arrays,
gene chips and biochips are often used to describe these
devices. The DNA microarray field is a combination of several
technologies, including automated DNA sequencing, DNA
amplification by PCR, oligonucleotide synthesis, nucleic acid
labeling chemistries and bioinformatics. Two most common
types of DNA microarrays include one in which the DNA
(in the form of a single stranded short oligonucleotide) is
synthesized in situ using photolithographic or other techniques
and another where the DNA (usually in the form of a cDNA
or full-length ORF) is post-synthetically attached to a solid
support (31,32).
Depending on the kind of probe (immobilized DNA) used
to generate the array and, ultimately, the information that is
derived from it, DNA microarrays are used for different
applications (33,34). As a definition in the context of
microarrays, a ‘probe’ is the (partial) genomic sequence of a
gene deposited and fixed on the Microarray, whereas the
‘target’ is the biological sample material.
Although there are many protocols and types of microarray
experiments, the basic steps involved in any microarray
experiment are isolating RNA or mRNA from appropriate
biological samples; applying a fluorescent tag to the RNA or
cDNA copy of it; hybridizing the labeled RNA or cDNA
(target) to a microarray (probe) for a period of time after which
the excess is washed off; scanning the microarray under laser
light and data analysis using appropriate software.
A brief description of three basic types of DNA
microarray experiments and their applications (35) is provided
in Table 1.
Applications of DNA Microarrays in Herbal
Drug Research and Development
Natural product research is often based on ethnobotanical
information and many of the drugs used today were employed
in indigenous societies (56). One of the aims of ethnopharma-
ceutical research is better understanding of the pharmacolo-
gical effects of different medicinal plants traditionally used in
healthcare (57). Plants are regarded as a promising source of
novel therapeutic agents due to their higher structural diversity
as compared to standard synthetic chemistry. Plants have
applications in the development of therapeutic agents: as a
source of bioactive compounds for possible use as drugs.
There are three approaches to natural product-based drug
Table 1. Basic types of DNA microarray experiments
Microarray type Brief description Applications References
Comparative genomic
hybridization (CGH)
Detect chromosomal aberrations Tumor classification
Disease diagnosis
Risk assessment
(36–42)
Expression analysis Analysis of gene expression levels Drug development
Drug response
Tracking disease progression
Therapy development
Drug mechanism of action
(43–49)
Mutation/polymorphism
analysis
Detect mutations/polymorphisms
in gene sequence
Drug development
Tracking disease progression
Disease risk assessment
Genotyping
Species identification
Population genetics
(50–55)
448 DNA microarrays in herbal drug researchdiscovery: screening of crude extracts; screening of pre-
fractionated extracts; screening of pure compounds (58).
In the past decade there has been a paradigm shift from
single-target drugs to multi-target drugs (59). Multi-target
approaches are directed toward activation of defence, protect-
ive and repair mechanisms of the body rather than destruction
of the damage-causing agent. This may be achieved by the use
of a combination of drugs as in AIDS, cancer, atherosclerosis
or use of single compounds that affect many targets simul-
taneously, e.g. Gleevec
TM, salicylate, metformin, Pemetrexed
(Alimta) and a multi-targeted antifolate (60,61). The concept
of multi-targeted therapy exists in traditional medical treat-
ments that employ multi-component extracts of natural
products. With the exception of pure substances, botanical
derivatives obtained from medicinal plants usually contain
several classes of compounds, which simultaneously act on
multiple targets. However, very few herbal medicinal products
have documentation comparable to synthetic drugs. Prepara-
tion of highly standardized herbal products with respect to
chemical composition and biological activity is complicated
due to the myriad range of chemicals. This also makes it
difficult to precisely predict the molecular targets, mechanism
of action and side effects of such products. Use of validated
analytical methods to quantify specific chemical markers
remains the key point to obtain chemically standardized
extracts (62). However many minor components with potential
biological effects remain neglected from quantitative analysis
of chemical markers. In the past years the development of
assays on the level of molecules (receptor binding and enzyme
inhibition) opened complete new perspectives for plant-based
products as source of new drugs (63). Advances in high-
throughput experimentation have resulted in massive data-
bases of genomic, proteomic and chemical data which in
combination with efficient separation methods and powerful
spectrometric methods for identification and structure eluci-
dation can be used for identification of active compounds.
In addition, the past two decades has witnessed a number
of citations that describe a diverse range of molecular
mechanisms that govern cellular behavior. A systems biology
approach that integrates such large and diverse sources of
information together will serve to make useful biological
predictions about the pharmacological effects of natural
products (64). DNA microarrays may provide a suitable
high-throughput platform for research and development of
drugs from natural products. In natural products a broad
repertoire of chemical entities act together on multiple targets
that makes it necessary to study the changes in expression of
multiple genes simultaneously. Novel technologies such as
SAGE and DNA microarrays allow rapid and detailed analysis
of thousands of transcripts, providing a revolutionary approach
to the investigation of gene expression.
In this review, we discuss the applications of DNA
microarray technology in herbal drug research and develop-
ment with suitable examples.
There are three main applications of DNA microarrays: first,
in pharmacodynamics for discovery of new diagnostic and
prognostic indicators and biomarkers of therapeutic response;
elucidation of molecular mechanism of action of a herb, its
formulations or its phytochemical components and identifica-
tion and validation of new molecular targets for herbal drug
development. Second, in pharmacogenomics for prediction of
potential side-effects of the herbal drug during preclinical
activity and safety studies; identification of genes involved
in conferring drug sensitivity or resistance and prediction of
patients most likely to benefit from the drug and use in general
pharmacogenomic studies. Third, in pharmacognosy for
correct botanical identification and authentication of crude
plant materials as part of standardization and quality control.
These applications are described here with some examples
(65–68). Figure 1 shows applications of DNA microarrays at
various stages of a typical drug discovery pipeline.
DNA microarrays in pharmacodynamics
Herbal products are usually whole herbs, their formulations or
extracts consisting of several bioactive compounds. With the
Figure 1. DNA microarray: applications in natural product drug discovery and development.
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herbal product there is a need for better understanding of the
molecular mechanisms underlying their biological activity.
Although, the physiological actions of many herbal drugs
are being studied at the molecular level, it remains unclear
what are the targets of individual phytochemical components
of herbs and how these molecules contribute to biological
activities. Examples of the applications of microarray-based
gene expression studies in elucidating molecular mechanism
of action of pure compounds, different phytochemical groups
and herbal extracts are discussed here. Figure 2 shows micro-
array based gene expression analysis of multi-component
mixtures and the information that can be obtained from such
studies.
Purified compounds/specific phytochemical groups
The molecular pathways underlying diverse biological activity
of the triterpenoid compounds isolated from the tropical
medicinal plant Centella asiatica when studied with gene
microarrays showed that Centella triterpenes evoke a gene-
expression response consistent with their prevailing medical
uses in the treatment of connective tissue disorders such as
wound healing and microangiopathy. The identification of
genes modulated by these compounds provides the basis for a
molecular understanding of Centella’s bioactivity, and oppor-
tunities for the quantitative correlation of this activity with
clinical effectiveness at a molecular level (69). Similarly, the
antiproliferative activity of Coptidis rhizoma, a medicinal
herb, and its major component berberine was investigated in
human pancreatic cancer cell lines. Gene expression patterns
associated with sensitivities to each agent were analyzed with
oligonucleotide arrays that comprised approximately 11,000
genes. It was possible to identify common and distinct genes
related to anti-proliferative activities of purified berberine and
C. rhizoma (70).
Involvement of genes in apoptosis inducing activity of
alkaloids from Chinese medicinal herb Tripterygium hypo-
glaucum (levl.) Hutch (Celastraceae) root was examined using
cDNA microarrays containing 3000 human genes derived
from a leukocyte cDNA library. Induction of apoptosis by
Tripterygium hypoglaucum alkaloids was found to be through
c-myc and NF-kappa B signaling pathways (71).
Gene expression pattern of inferior colliculus from DBA/2J
mice with audiogenic seizure and those treated with
Qingyangshenylycosides, a traditional Chinese medicine,
were examined. Gene expression analysis using Agilent oligo
microarray showed that total of 134 genes were either up- or
down-regulated during audiogenic seizure. Qingyangshenyly-
cosides prevented many of the audiogenic seizure induced
Figure 2. Microarray-based gene expression analysis of multi-component mixtures.
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genic seizure induced genes were further enhanced or reversed
by Qingyangshenylycosides treatment. The data provided
important information regarding the molecular mechanisms
of audiogenic seizure and the mechanism of action of
Qingyangshenylycosides (72).
Oligonucleotide microarrays consisting of 87 probes repre-
senting 87 human cardiovascular disease-related genes were
used to investigate the molecular mechanisms of saponins
from the rhizome of Anemarrhena asphodeloides Bunge. Gene
expression patterns in saponin treated and untreated human
umbilical vein endothelial cells were analyzed. The results
suggest that saponins may have beneficial effect on cardio-
vascular diseases by modulating the function of vein
endothelial cells (73).
A gene chip, (Rat Genome U34A) was used to elucidate the
gene regulatory pattern of Epimedium flavonoids in immune
homeostasis remodeling in the aged rats. Expression pattern
characterized by up-regulation of apoptosis promoting gene
expression and down-regulation of apoptosis inhibiting genes
expression, is the important gene background of immuno-
homeostasis imbalance in aged. Epimedium flavonoids reverse
these abnormal changes to reconstruct a beneficial equilibrium
of gene expression and thus to further remodel the immuno-
homeostasis in the aged (74).
Mechanism of herbal glycoside recipes retrieving deficient
ability of spatial learning memory in mice suffering from
cerebral ischemia/repurfusion was studied using DNA mico-
array system. Gene expression pattern was analyzed in the
groups that showed increased ability of spatial learning. A
1.8-fold increase in expression was observed for many genes
(38–46) including genes in cell cycle regulation, signal
transduction, nerve system transcription factors, DNA-binding
protein, etc. Nine genes related to retrieving deficient ability of
spatial learning memory when treated with glycoside recipes
were found in this study (75).
Chronic cocaine use is known to elicit changes in the pattern
of gene expression within the brain. The hippocampus plays
a critical role in learning and memory and may also play a
role in mediating behaviors associated with cocaine abuse. To
profile the gene expression response of the hippocampus to
chronic cocaine treatment, cDNA hybridization arrays were
used to illuminate cocaine-regulated genes in rats treated non-
contingently with a binge model of cocaine (76). Similarly,
using DNA microarray analysis gene expression changes with
chronic morphine and antagonist-precipitated withdrawal in
two brain regions involved in behavioral effects of morphine in
both mice and rats, were characterized (77).
Si-Jun-Zi decoction (SJZD), a traditional Chinese herbal
prescription, has been used clinically for treating patients
with disorders of the digestive system. Previous studies
indicated that the polysaccharides of SJZD are the active
components contributing towards its pharmacological effects
in improving gastrointestinal function and immunity. SJZD
polysaccharide was found to have protective effect and
enhanced re-epithelialization on wounded IEC-6 cells. To
elucidate the modulatory effect of polysaccharides of SJZD on
wounded IEC-6 cells at the molecular level, an oligonucleotide
microarray was employed to study differential gene expre-
ssion of treated IEC-6 cells and the candidate genes were
validated by RT–PCR. There was increased expression of
genes coding for ion channels and transporters, which
are critical to cell migration and restoration of wounded
intestinal cells, suggesting a possible mechanism for
re-epithelialization (78).
Clinical trials on antimicrotubule agents, docetaxel and
estramustine combination treatment have suggested improved
antitumor activity in hormone-refractory prostate cancer.
However, the molecular mechanisms involved in the combina-
tion treatment with docetaxel and estramustine have not been
fully elucidated. In order to establish such molecular mechan-
isms in both hormone insensitive and sensitive prostate cancer
cells, gene expression profiles of docetaxel- and estramustine-
treated prostate cancer cells were obtained by using Affyme-
trix Human Genome U133A Array. Clustering analysis based
on biological function showed that docetaxel and estramustine
combination treatment down-regulated some genes that are
known to regulate cell proliferation, transcription, translation,
and oncogenesis. In contrast, docetaxel and estramustine
combination treatment up-regulated some genes related to
induction of apoptosis, cell cycle arrest, and tumor suppres-
sion. Docetaxel and estramustine also showed differential
effects on gene expression between mono- and combination
treatment. Combination treatment with docetaxel and estra-
mustine caused alternations of a large number of genes, many
of which may contribute to the molecular mechanisms by
which docetaxel and estramustine inhibit the growth of
prostate cancer cells. These results provide novel molecular
targets of docetaxel and estramustine combination treatment
in prostate cancer cells (79).
Extracts
High-density oligonucleotide microarrays have been used for
pioneer studies on the multiple gene expression effects
exhibited by Ginkgo biloba leaf extract EGb 761, changing
traditional pharmacology and medicine concepts (80). EGb
761 has been known to have neuroprotective effects ranging
from molecular and cellular, to animal and human studies,
however, the mechanisms remain unclear. DNA microarray
based analyses has largely helped in identifying its targets
and mechanism of action. High-density oligonucleotide
microarrays were used to define the transcriptional effects
in the cortex and hippocampus of mice whose diets were
supplemented with the herbal extract. This study reveals that
diets supplemented with Ginkgo biloba extract have notable
neuromodulatory effects in vivo and illustrates the utility of
genome-wide expression monitoring to investigate the biolo-
gical actions of complex extracts (81). Further, DNA microar-
ray analyses revealed that transcription of multiple apoptosis-
related genes is either up- or down-regulated in cells treated
with EGb 761. These results suggest that inhibition of
apoptotic machinery may, at least in part, mediate multiple
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cytostatic action of EGb 761 was elucidated with the help of
DNA microarray and the genes important for tumor growth
were identified (83).
Ginkgo extract and one of its terpenoid constituents,
ginkgolide B, inhibited the proliferation of a highly
aggressive human breast cancer cell line and xenografts of
this cell line in nude mice. cDNA microarray analyses have
shown that exposure of human breast cancer cells to a Ginkgo
extract altered the expression of genes that are involved in
the regulation of cell proliferation, cell differentiation or
apoptosis, and that exposure of human bladder cancer cells
to a Ginkgo extract produced an adaptive transcriptional
response that augments antioxidant status and inhibits DNA
damage (84).
A human genome screen for TNFa-inducible genes was
used to identify the genetic basis of the anti-inflammatory
effects of standardized Boswellia serrata extract, 5-Loxin in
microvascular endothelial cells. Acutely, TNFa-induced 522
genes; of which 113 genes were clearly sensitive to 5-Loxin
treatment. Such genes directly related to inflammation, cell
adhesion, and proteolysis. The robust 5-Loxin -sensitive
candidate genes were then subjected to further processing
which led to the recognition of the primary 5-Loxin -sensitive
TNFa-inducible pathways. One mechanism by which TNFa,
causes inflammation is by potently inducing the expression
of adhesion molecule VCAM-1. 5-Loxin was found to
completely inhibit VCAM-1 expression (85).
Water-extract of Paeoniae Radix has inhibitory effect on
the growth of both HepG2 and Hep3B cell lines. Using cDNA
microarray technology and RT–PCR analysis the drug targets
of Paeoniae Radix in inhibition of tumor cells growth were
elucidated (86).
Several studies have indicated that extracts of S. barbata
have growth inhibitory effects on a number of human cancers.
However, the mechanism underlying the antitumor activity
was unclear. cDNA microarray analysis showed that 16 genes,
involved in DNA damage, cell cycle control, nucleic acid
binding and protein phosphorylation, underwent more than
5-fold change. These data indicated that these processes are
involved in S. barbata-mediated killing of cancer cells (87).
The effect of Syzygium aromaticum (L.) Merrill and Perry
(clove) extract on tissues that regulate glucose metabolism
was studied by analysis of gene expression using DNA
microarray. The data showed that the extract acts like insulin
in hepatocytes and hepatoma cells by reducing phosphoenol-
pyruvate carboxykinase and glucose 6-phosphatase gene
expression. Much like insulin, clove-mediated repression was
reversed by PI3K inhibitors and N-acetylcysteine. Moreover,
clove and insulin were found to regulate the expression of
many of the same genes in a similar manner. These results
indicate a potential role for compounds derived from clove as
insulin-mimetic agents (88).
A cDNA microarray study demonstrated significant
inhibition of inducible endothelial CD36 expression, a novel
cardioregulatory gene, by IH636 grape seed proanthocyanidin
extract (89).
Both the prototypic tricyclic antidepressant imipramine
(IMI) and the extract of St John’s wort (SJW) can be effective
in the treatment of major depressive disorder. Affymetrix
chips were used to study hypothalamic gene expression in rats
treated with SJW or IMI to test the hypothesis that chronic
antidepressant treatment by various classes of drugs results in
shared patterns of gene expression that may underlie their
therapeutic effects. SJW treatment differentially regulated 66
genes and expression sequence tags (ESTs) and IMI treatment
differentially regulated 74 genes and ESTs. Six common trans-
cripts in response to both treatments were found. Both
treatments also affected different genes that are part of the
same cell function processes, such as glycolytic pathways and
synaptic function. The data support the hypothesis that chronic
antidepressant treatment by drugs of various classes may result
in a common, final pathway of changes in gene expression in
a discrete brain region (90).
Recently, a rapid throughput screening system involving
gene expression analysis was developed in order to investigate
the potential of bioactive chemicals contained in natural health
products as effective drug therapy, in particular the ability of
these chemicals to alleviate the inflammatory response in
human airway epithelial cells (91).
The pharmacogenomic activities of Anoectochilus formosa-
nus extract as a crude phytocompound mixture were compared
to those conferred by the single-compound drug, plumbagin
in MCF-7 cancer cells. This study offers evidence to support
the search for fractionated medicinal herb extracts or
phytocompound mixtures, in addition to single-compound
drugs, as defined therapeutic agents (92). DNA microarray can
be used for activity-guided fractionation of herbal extracts in
order to determine active principles.
DNA microarrays in Pharmacogenomics
Pharmacogenomics is the study of genes and the gene products
(proteins) essential for pharmacological or toxicological
responses to pharmaceutical agents. Oligonucleotide-based
DNA chip technology or cDNA microarray can be used to
analyze gene expression profiles that are induced or repressed
by xenobiotics (93).
An attempt has been made to develop microarray genotyping
system for multiplex analysis of a panel of single nucleotide
polymorphisms (SNPs) in genes encoding proteins involved in
blood pressure regulation, and to apply this system in a pilot
study demonstrating its feasibility in the pharmacogenetics of
anti-hypertensive drug response (94). DNA microarray techni-
ques might prove to be a reliable basis for predicting response
(or lack of response) of individuals to herbal drugs.
Technologies designed to characterize genes and their
products on a discovery scale are now having an impact on
many areas of biology, including toxicology. Toxicogenomics
is the sub-discipline that merges genomics with toxicology.
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mechanism-based research on toxicant action by comparing
results for an experimental compound with a database.
Recently several studies have demonstrated the utility of
microarray analysis for studying genome-wide effects of
xenobiotics and the rapid identification of toxic hazards for
novel drug candidates (95,96).
An example of such a platform is ToxBlot II, a custom
microarray containing cDNAs representing 12564 human
genes chosen on the basis of their potential relevance to a
broad range of toxicities. ToxBlot II allows the simultaneous
expression profiling of genes representing entire cellular
pathways, facilitating a very detailed investigation of potential
mechanisms of toxicity (97). cDNA microarray analysis was
used to study the expression level of genes in oral fibroblast
cell lines in response to exposure to ripe areca nut extract. The
results showed up-regulation of IL-6 expression and down-
regulation of PDGFR, APP-1 and KGF-1 expressions in
multiple cell lines assayed. The down-regulation of KGF-1
expression in oral fibroblast cell lines potentially impairs the
proliferation of overlying keratinocytes, which could partially
explain the frequent epithelial atrophy observed in chronic
areca chewers in vivo. This study established a novel toxico-
genomic database for areca nut extract (98). cDNA microarray
analysis was also used to analyze the mRNA expression
patterns of 1177 genes in ten oral cancer patients with betel
quid chewing history. This study provides pilot data for
understanding the pathogenesis of oral cancer in countries like
Taiwan where betel quid chewing is prevalent (99).
Recent studies have highlighted that concurrent use of herbs
may mimic, magnify, or oppose the effect of drugs (100,101).
DNA microarray can be used for studying herb–drug inter-
actions, and the mechanisms underlying these interactions.
Several botanical constituents in PC-SPES, a botanical
preparation, inhibit tumor growth through cell cycle arrest and
apoptosis. LNCaP prostate carcinoma cells were treated with
PC-SPES, and changes in gene expression were determined by
complementary DNA (cDNA) microarray hybridization and
northern blot analyses. mRNA levels of a-tubulin decreased
sevenfold. The results show that PC-SPES may interfere
with microtubule polymerization. This activity has implica-
tions for the clinical management of patients with advanced
prostate cancer who may be taking PC-SPES concurrently
with microtubule-modulating chemotherapeutic agents, such
as paclitaxel (102). cDNA microarray analysis was used to
identify gene expression changes in LNCaP prostate carci-
noma cells exposed to PC-SPES and estrogenic agents
including diethylstilbestrol. Transcripts encoding cell cycle-
regulatory proteins, a- and b-tubulins, and the androgen
receptor were down-regulated by PC-SPES. A comparison of
gene expression profiles resulting from these treatments
indicates that PC-SPES exhibits activities distinct from those
attributable to diethylstilbestrol and suggests that alterations
in specific genes involved in modulating the cell cycle, cell
structure, and androgen response may be responsible for
PC-SPES-mediated cytotoxicity (103).
DNA microarray in pharmacognosy
Use of authentic herbal materials is the first step to ensure
quality, safety and efficacy of herbal medicines. DNA
polymorphism-based assays have been developed for the
identification of herbal medicines (104,105). In this approach,
small amounts of DNA are amplified by the polymerase chain
reaction and the reaction products are analyzed by gel electro-
phoresis, sequencing, or hybridization with species-specific
probes. Recently, microarrays have been applied for the DNA
sequence-based identification of medicinal plants (106,107).
To utilize DNA microarrays for identification and authenti-
cation of herbal material, it is necessary to identify a distinct
DNA sequence that is unique to each species of medicinal
plant. The DNA sequence information is then used to synthe-
size a corresponding probe on a silicon-based gene chip. These
probes are capable of detecting complementary target DNA
sequences if present in the test sample being analyzed.
Oligonucleotide probes specific for polymorphisms in the
D2 and D3 regions of 26S rDNA gene of several Fritillaria
species were designed and printed on the poly-lysine coated
slides to prepare a DNA chip. Differentiation of the various
Fritillaria species was accomplished based on hybridization
of fluorescent labeled PCR products with the DNA chip. The
results demonstrated the reliability of using DNA chips to
identify different species of Fritillaria, and that the DNA
chip technology can provide a rapid, high throughput tool for
genotyping and plant species authentication (108).
Similarly, using fluorescence-labeled ITS2 sequences as
probes, distinctive signals were obtained for the five medicinal
Dendrobium species listed in the Chinese Pharmacopoeia.
The established microarray was able to detect the presence of
D. nobile in a Chinese medicinal formulation containing nine
herbal components (109).
A silicon-based DNA microarray using species-specific
oligonucleotide probes is designed and fabricated to identify
multiple toxic traditional Chinese medicinal plant species
by parallel genotyping (110). Chip-based authentication of
medicinal plants may be useful as economical, precise tool
for quality control and safety monitoring of herbal
pharmaceuticals and neutraceuticals.
Identification of herbal materials, which commonly consist
of dried or processed parts, is difficult. This is particularly
true for similar looking herbal materials that can often vary
greatly in their medicinal properties and market value.
DNA microarray based technology can provide an efficient,
accurate and cheaper means of testing the authenticity of
hundreds of samples simultaneously while conventional
chemical methodologies usually take several days for verifi-
cation. Chip-based authentication of medicinal plants can
be useful as a tool for quality control and safety monitoring
of herbal pharmaceuticals and neutraceuticals and will signi-
ficantly add to the medical potential and commercial
profitability of herbal products.
This application of DNA microarrays will not only benefit
the herbal drug industry but can also facilitate the identifi-
cation of herbal products by regulatory authorities. An
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(CBOL) is devoted to developing DNA barcoding as a tool for
correct taxonomic identification of species, including medi-
cinal plants. DNA microarrays can provide a suitable
technology platform for such an initiative.
Perspective
Traditionally, the pharmaceutical industry has focused on
modifying one gene or protein at a time as the basis for
identifying new drugs. The quest for a molecule to modify a
single key factor in a disease process may not provide a
solution for many complex diseases where multiple cell types
and/or multiple pathways contribute to disease. Herbal extracts
or mixtures represent combinatorial chemistry of nature with
vast repertoire of chemical entities that have a complex effect
on numerous cellular components and functions. They have
great potential in the multi-target approach to diseases.
However, potential of herbal drugs as defined therapeutic
agents is undermined by the difficulty in standardization,
pharmacodynamics and pharmacokinetics of these multi-
component mixtures. Microarray analysis of gene expression
can be useful for elucidating the molecular mechanisms and
networks underlying the complex pharmacological function
of herbal extracts and mixtures. Studying the patterns of gene
expression at many stages during the treatment process can
reveal mechanism from a modern genetic perspective and
will help to identify biomarkers of adverse or favorable
response. A positive correlation between the transcriptional
response induced by an herbal drug and a database profile of
an existing therapeutic agent can provide insight into target
specificity, mechanism of action, as well as facilitate analysis
of pathways downstream of the target. It will also help in
identification of novel therapeutic applications of a herbal
drug. DNA microarrays can also be used for activity-guided
fractionation of herbal extracts thereby helping in narrowing
down upon the active principle producing the desired effect.
Microarrays have applications in the entire drug discovery
pipeline to improve selection of biological targets and lead
compounds. Correlation of gene expression data of herbal drug
candidates with clinical outcome or biomarkers of response
in biological system will facilitate selection of best candidate
for drug development.
In the area of pharmacogenomics, DNA microarrays will
facilitate development of individually optimized drugs based
on differential gene expression patterns. Genetic polymor-
phism studies can be done to classify individuals according
to their drug metabolizing capacities or response to disease
(111). SNP screening of patients undergoing treatment with a
particular herbal drug and correlating these data with reco-
very profile would help to understand which individuals or
groups are likely to be benefited by the drug. Microarray
analysis of gene expression has become a suitable approach for
the biological effects of drugs and other chemicals. Gene
expression profile screens focused on genes that are relevant to
toxicity can be useful for prediction of potential herbal drug
side effects during pre-clinical development and toxicology
studies. They can also be applied for studying herb–drug
interactions and their underlying mechanisms.
Medicinal plants are an integral part of TM/CAM such as
Ayurvedic, Chinese, Native American and many other
traditional systems of medicine. Clinical experiences, obser-
vations or documented data becomes a starting point for
traditional knowledge based drug development. Although the
clinical existence of traditional medicine spans several gene-
rations, it may be hazardous to extrapolate from such uses to
current practice, since herbs and or their formulations used
may be very different from the commercial herbal products
available today. Many questions remain concerning quality,
efficacy, safety, bioavailability and mechanisms of action of
even the most widely used herbs. These questions can be
answered by rigorous application of scientific principles in
high quality basic and clinical research. There is a need for
scientific validation of safety, efficacy, therapeutic claims,
bioavailability and mechanism of action of these medicines
that are being used in the population since centuries.
Microarray based approach can facilitate high throughput,
fast track evidence-based herbal drug development following
Reverse Pharmacology path. Phytomics, a technology plat-
form for characterization of herbal compositions wherein,
Herbal Bio Response Arrays (HBR Arrays) are used to deter-
mine bioactive constituents and biological activities of an
herbal composition has recently been developed and
patented (112).
Further, CAM disciplines owing to their holistic nature may
be impacting gene expression and signaling pathways (113).
Application of such novel expression analysis tools may help
to understand and characterize the genes and signaling
pathways involved in CAM modalities.
DNA microarrays have the potential for application in
different phases of herbal drug discovery and development.
This includes quality control and standardization of the herbal
drugs, identification and validation of new targets, the profi-
ling of on-target and off-target effects during the optimization
of new therapeutic agents, understanding molecular mecha-
nisms of action, structure–activity relationships (114) and the
prediction of side-effects, and the discovery of diagnostic,
prognostic, and pharmacodynamic biomarkers.
At present the major practical applicability of DNA
microarrays remains in SNP mapping, genotyping and
pharmacogenetics. In recent years, array-based sequencing
(minisequencing/resequencing arrays) that combines target
hybridization with enzymatic primer extension reactions has
emerged as a powerful means to scan for all possible DNA
sequence variations (115–117). Highly multiplexed microar-
ray systems offering potential for mutation analysis (118,119)
and genome-wide SNP mapping (120) have been developed.
DNA microarrays are a effective new strategy for global
gene expression profiling, but reliable detection of expression
changes and understanding the functional relevance of these
expression profiles is a challenge. Other problems in micro-
array experiments include non-reproducibility, difficulty in
454 DNA microarrays in herbal drug researchstatistical analysis and comparability of data from different
experiments (121). Inconsistencies in data may arise due to
low specificity of cDNA probes, discrepancy in fold-change
calculations, variations in laboratories, technicians, probe
labeling, biochemical reactions, scanners, lasers etc (122).
Also the sensitivity and specificity of DNA microarrays
depends on the nucleotide composition of the target and
probe. Repetitive sequence elements and highly structured
nucleic acids can greatly decrease the sensitivity of hybridiza-
tion based analysis. In its current stage, a microarray experi-
ment needs to be validated by independent confirmation of
results by laboratory-based analysis and in silico comparison
with information available in literature and expression data-
bases (123). Although DNA microarrays have huge potential
for pharmacodynamics and toxigenomics applications, these
are still in exploratory stage and need validation by other
biological experiments. Bioinformatics and statistical tools
have a major role to play in the microarray field, whereby
data from multiple experiments can be integrated to answer
complex biological questions. Another factor limiting
microarray application is the cost of the technology. The
challenge today is to provide standardized, sensitive, repro-
ducible microarray platforms, databases and visualization
methods for expression profiles that are also affordable to
scientists. With the development of new, uniform and more
sophisticated experimental designs, data management systems
(124,125) statistical tools and algorithms for data analysis
(126,127) DNA microarrays can be optimally used in herbal
drug research. In spite of the huge potential offered by
microarray technology, the importance of in vitro biological
assays, cell-line studies and in vivo animal studies cannot be
ignored. A comprehensive strategy integrating information
from diverse scientific experiments and technologies will lead
to molecular evidence-based herbal medicine.
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